AP -- CV Therapeutics Inc. said Wednesday it is reviewing a buyout offer from partner Astellas Pharma Inc., which it had initially rejected. CV turned down the $1 billion bid in November. CV Therapeutics said it decided that offer was not in the best interest of the company or its shareholders, but after Astellas made the bid public Tuesday, CV said it will consider it again in light of changes in the market and its own business.
